SARS-CoV-2 Mpro-IN-4
SARS-CoV-2 Mpro-IN-4 is a dual Inhibitor of Main Protease (MPro) and Cathepsin L (CatL), with IC50s of 900 nM and 60 nM respectively. SARS-CoV-2 Mpro-IN-4 has antiviral activity against SARS-CoV2. SARS-CoV-2 Mpro-IN-4 blocks SARS-CoV2 replication in hACE2 expressing A549 cells with IC50 value of 8.2 nM.
For research use only. We do not sell to patients.
- Formula: C30H38N4O5
- Molecular Weight:534.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
MPro/CatL[1]
In Vitro
SARS-CoV-2 Mpro-IN-4 (SM141) blocks SARS-CoV2 replication in A549-hACE2 cells with IC50 value of 8.2 nM[1].
SARS-CoV-2 Mpro-IN-4 (50 μM, 24 h) does not cause any notable cytotoxicity in A549-hACE2 cells[1].
SARS-CoV-2 Mpro-IN-4 inhibits OC-43 virus mRNA expression A549 cells[1].
SARS-CoV-2 Mpro-IN-4 inhibits SARS-CoV2 infection by inhibiting both MPro and CatL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
SARS-CoV-2 Mpro-IN-4 (3 mg/kg, i.v.) shows a short half-life of 0.8 h and high clearance of 72 mL/min/kg in in male C57Bl/6 mice[1].
SARS-CoV-2 Mpro-IN-4 (10 mg/kg, p.o.) shows oral bioavailability of 5%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:K18-hACE2 transgenic mice[1]
-
Dosage:10 mg/kg (i.n.) or 25 mg/kg (i.p.)
-
Administration:Intranasal inhalation (i.n.), once daily for 3 days, prior to the infection; or Intraperitoneal injection (i.p.), twice daily for 5 days, postinfection administration.
-
Result:Prevented weight loss and prolonged survival.
Chemical Information
-
Molecular Weight 534.65
-
Formula C30H38N4O5
-
SMILES
CN[C@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@@H](C[C@@H]2CCNC2=O)/C=C/C(OCC)=O)=O)CC3=CC=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)